Gilead Sciences, Inc. (GILD)
Market Cap | 132.09B |
Revenue (ttm) | 28.74B |
Net Income (ttm) | 5.97B |
Shares Out | 1.24B |
EPS (ttm) | 4.73 |
PE Ratio | 22.45 |
Forward PE | 13.05 |
Dividend | $3.16 (2.98%) |
Ex-Dividend Date | Jun 13, 2025 |
Volume | 8,150,570 |
Open | 108.82 |
Previous Close | 108.50 |
Day's Range | 105.35 - 109.44 |
52-Week Range | 66.01 - 119.96 |
Beta | 0.31 |
Analysts | Buy |
Price Target | 110.17 (+3.75%) |
Earnings Date | Aug 7, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $110.17, which is an increase of 3.75% from the latest price.
News
Gilead Sciences CEO Daniel O'Day on HIV prevention injection approval
Gilead Sciences CEO Daniel O'Day explains why he believes the biopharma's HIV prevention injection Yeztugo, which received approval from the Food and Drug Administration last week, is a "milestone mom...
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences chairman and CEO Daniel O'Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importan...

AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention
LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention.

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable...

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending t...

US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

Should You Buy Gilead Stock At $110?
Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performa...

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gilead Sciences, Inc. (GILD) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Initiate Gilead Sciences with Strong Buy/$181 PT, citing disciplined cost base, accelerating pipeline, and robust Q1-25 execution driving margin and EPS outperformance. HIV franchise resilience and up...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants...

US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday.
Final Trade: NVO, CELH, LION, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.'s GILD New Drug Application (NDA) submissions for lenacapavir — the company's twice-yearly injectable HIV-1 caps...

Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies Global Healthcare Conference June 4, 2025 11:05 PM ET Company Participants Cindy Perettie - Executive Vice President of Kite Dietmar P. Berger - Chief Me...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Gilead's CAR-T cell therapy shows promise in deadly brain cancer
A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment opti...

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patient...

Potentially Earn 12%-15% Income: Monthly Options Series (June 2025)
We explain why selling cash-covered puts and covered calls is a relatively safe choice for earning high income. We will discuss how to formulate a sustainable and repeatable income strategy for option...

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, acc...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression...

Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Admini...